NKILT Therapeutics

Raphael Ognar, Co-Founder and CEO

April 12 | 2:15pm | Dark Horse Consulting Ballroom 

Springfield, NJ


NKILT Therapeutics is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. In vitro PoC has been confirmed. Our initial platform is based on a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells, but will also activate innate immunity and directly target the tumor’s defense mechanisms. The first indication will be Acute Myeloid Leukemia (AML) as a preclinical and clinical proof of concept, expanding rapidly our core focus in a large array of solid tumors such as Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and more HLA-G+ tumors.


By using this website you agree to accept our Privacy Policy and Terms & Conditions